Arndt Vogel

Arndt Vogel: Efficacy of zanidatamab in HER2 positive advanced biliary tract cancers

Arndt Vogel,Β Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared an article by Cristina Smolenschi,Β et al. on X:

“Real-world efficacy of zanidatamab in HER2 positive advanced biliary tract cancers.

  • RWD.
  • ORR 40%, DCR 65%.
  • mPFS 6.7mo, 1-yr OS 80%.
  • Higher efficacy in 3+ vs 2+.
  • Confirmed benefit for Zanidatamab.”

Arndt Vogel: Efficacy of zanidatamab in HER2 positive advanced biliary tract cancers

Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers.

Authors: CristinaΒ Smolenschi,Β et al.

Arndt Vogel: Efficacy of zanidatamab in HER2 positive advanced biliary tract cancers

Arndt Vogel Biliary tract cancers cancer π„π§ππ¨πœπ«π’π§π¨π₯𝐨𝐠𝐲 fight against cancer Gastroenterology Global fight against cancer Hannover Medical School Hepatology HER2-positive OncoDaily Oncology Zanidatamab